Physician

Raminder P Mand, M.D.

According to 2025 Medicare claims, Raminder Mand, M.D. (NPI: 1609032358) practices nephrology in the Modesto, CA market, with the plurality of this provider's patient population coming from Stanislaus, CA. This provider's primary affiliated billing organization is RAMINDER MAND, MD INC. (NPI: 1720480205; TIN: 461275775) and primary practice location at 95382-1544.

Mand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 643 traditional Medicare patients, billed 3,706 HCPCS/CPT codes, and received $405,413 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,307 prescription claims across 419 beneficiaries totaling $422,189 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 26 claims. Open Payments data shows 34 records totaling $831. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $184,228 and ending at $422,189. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	768	3,959	$411,280
2016	725	3,992	$403,569
2017	708	4,243	$400,214
2018	721	4,038	$379,667
2019	687	3,793	$396,653
2020	750	4,363	$446,289
2021	678	3,873	$449,389
2022	666	4,373	$438,021
2023	647	4,022	$416,677
2024	643	3,706	$405,413

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	121	1,214	$184,228
2016	134	1,823	$299,365
2017	157	2,122	$461,295
2018	186	2,279	$331,954
2019	196	1,906	$249,723
2020	219	1,741	$245,226
2021	272	2,365	$179,805
2022	325	2,635	$281,708
2023	396	3,085	$432,476
2024	419	3,307	$422,189

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	23	$1,059
2018	N/R	24	$862
2019	N/R	N/R	N/R
2020	N/R	13	$908
2021	N/R	11	$562
2022	N/R	N/R	N/R
2023	N/R	23	$139
2024	N/R	26	$682

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	143	191	$146
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	186	191	$138
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	178	447	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	302	707	$94
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	225	980	$64

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	97	3,630	$65,630
Lokelma	Sodium Zirconium Cyclosilicate	71	3,126	$60,091
Velphoro	Sucroferric Oxyhydroxide	14	600	$44,600
Veltassa	Patiromer Calcium Sorbitex	26	1,305	$35,575
Sevelamer Carbonate	Sevelamer Carbonate	170	9,114	$34,257

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0260	Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress	Y	N/R	12	$526
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	N/R	14	$156

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$831	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Raminder P. Mand, M.D.?

Tedicare shows public-source Medicare data for Raminder P. Mand, M.D. (NPI 1609032358), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Raminder P. Mand, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Raminder P. Mand, M.D.?

Raminder P. Mand, M.D. is linked to RAMINDER MAND, MD INC. (billing NPI 1720480205) in the available physician profile data.

Does Raminder P. Mand, M.D. have Open Payments data?

Raminder P. Mand, M.D. has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.